Folge 06 – Was am Ende zählt – Die ESR1-Therapie
Post-hoc Analyse von Subgruppen aus der EMERALD Studie1
mPFS Vorteil von Elacestrant vs. SOC unabhängig von:
- Metastasen-Lokalisation
- PIK3CA-Comutation
- HER2-low Expression
- TP53-mut
1) Bardia A, et al. Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups. Clin Cancer Res 2024; https://doi.org/10.1158/1078-0432.CCR-24-1073
